ABSTRACT
Phospholipids become increasingly important as formulation excipients and as active ingredients per se. The present article summarizes particular features of commonly used phospholipids and their application spectrum within oral drug formulation and elucidates current strategies to improve bioavailability and disposition of orally administered drugs. Advantages of phospholipids formulations not only comprise enhanced bioavailability of drugs with low aqueous solubility or low membrane penetration potential, but also improvement or alteration of uptake and release of drugs, protection of sensitive active agents from degradation in the gastrointestinal tract, reduction of gastrointestinal side effects of non-steroidal anti-inflammatory drugs and even masking of bitter taste of orally applied drugs. Technological strategies to achieve these effects are highly diverse and offer various possibilities of liquid, semi-liquid and solid lipid-based formulations for drug delivery optimization.
Similar content being viewed by others
REFERENCES
Anand BS, Romero JJ, Sanduja SK, Lichtenberger LM. Phospholipid association reduces the gastric mucosal toxicity of Aspirin in human subjects. Am J Gastroenterol. 1999;94:1818–22.
Arien A, Henry-Toulme N, Dupuy B. Calcitonin loaded liposomes: stability under acidic conditions and bile salts-induced disruption resulting in calcitonin–phospholipid complex formation. Biochim Biophys Acta. 1994;1193:93–100.
Bekerman T, Golenser J, Domb A. Cyclosporin nanoparticulate lipospheres for oral administration J. Pharm Sci. 2004;93:1264–70.
Borgstrom B, Dahlquist A, Lundh G, Sjovall J. Studies of intestinal digestion and absorption in the human. J Clin Invest. 1957;36:1521–36.
Caliph SM, Charman WN, Porter CJH. Effect of short-, medium-, and long-chain fatty acid based vehicles on the absolute oral bioavailability and intestinal lymphatic transport of halofantrine and assessment of mass balance in lymph-cannulated and non-cannulated rats. J Pharm Sci. 2000;89:1073–84.
Cao J, Sun J, Wang X, Li X, Deng Y. N-Trimethyl chitosan-coated multivesicular liposomes for oxymatrine oral delivery. Drug Dev Ind Pharm. (2009). Epub ahead of print].
Carlson RP, Hartman DA, Ochalski SJ, Zimmerman JL, Glaser KB. Sirolimus (rapamycin, Rapamune) and combination therapy with cyclosporin A in the rat developing adjuvant arthritis model: correlation with blood levels and the effects of different oral formulations. Inflamm Res. 1998;47:339–44.
Carriere F, Barrowman JA, Verger R, Laugier R. Secretion and contribution to lipolysis of gastric and pancreatic lipases during a test meal in humans. Gastroenterology. 1993;105:876–88.
Chakraborty S, Shukla D, Mishra B, Singh S. Lipid—an emerging platform for oral delivery of drugs with poor bioavailability. Europ J Pharm Biopharm. 2009;73:1–15.
Chen Y, Lu Y, Chen J, Lai J, Sun J, Hu F et al. Enhanced bioavailability of the poorly water-soluble drug fenofibrate by using liposomes containing a bile salt. Int J Pharm. 2009;376:153–60.
Chen Y, Ping Q, Guo J, Lv W, Gao J. The absorption behavior of cyclosporin A lecithin vesicles in rat intestinal tissue. Int J Pharm. 2003;261:21–6.
Chen X, Young TJ, Sarkari M, Williams 3rd RO, Johnston KP. Preparation of cyclosporine A nanoparticles by evaporative precipitation into aqueous solution. Int J Pharm. 2002;21:3–14.
Cui F, Shi K, Zhang L, Tao A, Kawashima Y. Biodegradable nanoparticles loaded with insulin-phospholipid complex for oral delivery: preparation, in vitro characterization and in vivo evaluation. J Contr Rel. 2006;28:242–50.
Czogalla A. Oral cyclosporine A—the current picture of its liposomal and other delivery systems. Cell Mol Biol Lett. 2009;14:139–52.
Değim IT, Gümüşel B, Değim Z, Ozçelikay T, Tay A, Güner S. Oral administration of liposomal insulin. J Nanosci Nanotechnol. 2006;6:2945–9.
Delmas G, Park S, Chen ZW, Tan F, Kashiwazaki R, Zarif L et al. Efficacy of orally delivered cochleates containing amphotericin B in a murine model of aspergillosis. Antimicrob Agents Chemother. 2002;46:2704–7.
Dial E, Zayat M, Lopez-Storey M, Tran D, Lichtenberger L. Oral phosphatidylcholine preserves the GI mucosal barrier during LPS-induced inflammation. Shock. 2008;30:729–33.
Dunjic BS, Axelson J, Ar’Rajab A, Larsson K, Bengmark S. Gastroprotective capability of exogenous phosphatidylcholine in experimentally induced chronic gastric ulcer in rats. Scand J Gastroenterol. 1993;28:89–94.
Dvir E, Friedman JE, Lee JY, Koh JY, Younis F, Raz S et al. A novel phospholipid derivative of indomethacin, DP-155 [mixture of 1-steroyl and 1-palmitoyl-2-{6-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl-3-indolyl acetamido]hexanoyl}-sn-glycero-3-phosophatidyl [corrected] choline], shows superior safety and similar efficacy in reducing brain amyloid beta in an Alzheimer’s disease model. J Pharmacol Exp Ther. 2006;318:1248–56.
Dvir E, Elman A, Simmons D, Shapiro I, Duvdevani R, Dahan A et al. DP-155, a Lecithin Derivative of Indomethacin, is a novel nonsteroidal antiinflammatory drug for analgesia and alzheimer’s diease therapy. CNS Drug Rev. 2007;13:260–77.
Fini A, Bergamante V, Ceschel GC, Ronchi C, de Moraes CA. Fast dispersible/slow releasing ibuprofen tablets. Eur J Pharm Biopharm. 2008;69:335–41.
Fukunaga M, Miller MM, Deftos LJ. Liposome entrapped calcitonin and parathyroid hormone are orally effective in rats. Horm Metab Res. 1991;23:166–7.
Gao D, Han L, Wang J. Self-micro emulsifying drug delivery system loaded with gentiopicrin phospholipid complex for oral delivery: preparation, in vitro characterization and in vivo evaluation. Abstract 2009 AAPS Annual Meeting and Exposition 11/7/2009–11/12/2009 (http://abstracts.aapspharmaceutica.com/ExpoAAPS09/CC/forms/attendee/index.aspx?Content=sessionInfo&sessionId=278).
Garcia-Fuentes M, Prego C, Torres D, Alonso M. A comparative study of the potential of solid triglyceride nanostructures coated with chitosan or poly(ethylene glycol) as carriers for oral calcitonin delivery. Eur J Pharm Sci. 2005;25:133–43.
Garcia-Fuentes M, Torres D, Alonso MJ. New surface-modified lipid nanoparticles as delivery vehicles for salmon calcitonin. Int J Pharm. 2005;296:122–32.
Ge Z, Zhang XX, Gan L, Gan Y. Redispersible, dry emulsion of lovastatin protects against intestinal metabolism and improves bioavailability. Acta Pharmacol Sin. 2008;29:990–7.
Gershanik T, Benzeno S, Benita S. Interaction of a self-emulsifying lipid drug delivery system with the everted rat intestinal mucosa as a function of droplet size and surface charge. Pharm Res. 1998;15:863–9.
Giraud M-N, Motta C, Romero JJ, Bommelaer G, Lichtenberger LM. Interaction of Indomethacin and Naproxen with gastric surface-active phospholipids: A possible mechanism for the gastric toxicity of nonsteroidal anti-inflammatory drugs (NSAIDs). Biochem Pharmacol. 1999;57:247–54.
Ghyczy M, Hoff E, Gareiß J. Gastric mucosa protection by phospha-tidylcholine (PC). Prog Drug Deliv Syst. 1996;V:49–51.
Guo J, Ping Q, Chen Y. Pharmacokinetic behavior of cyclosporin A in rabbits by oral administration of lecithin vesicle and Sandimmun Neoral. Int J Pharm. 2001;216:17–21.
Hauss DJ, Fogal SE, Ficorilli JV, Price CA, Roy T, Jayaraj AA, Keirns JJ. Lipidbased delivery systems for improving the bioavailability and lymphatic transport of a poorly water-soluble LTB4 inhibitor. J Pharm Sci. 1998;87:164–9.
He J, Hou S, Lu W, Zhu L, Feng J. Preparation, pharmacokinetics and body distribution of silymarin-loaded solid lipid nanoparticles after oral administration. J Biomed Nanotechnol. 2007;3:195–202.
Holm R, Mullertz A, Pedersen GP, Kristensen HG. Comparison of the lymphatic transport of halofantrine administered in dispersed systems containing three different unsaturated fatty acids. Pharm Res. 2001;18:1299–304.
Hu SX, Soll R, Yee S, Lohse DL, Kousba A, Zeng B et al. Metabolism and pharmacokinetics of a novel Src kinase inhibitor TG100435 ([7-(2,6-dichloro-phenyl)-5-methyl-benzo[1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-amine) and its active N-oxide metabolite TG100855 ([7-(2,6-dichloro-phenyl)-5-methylbenzo[1,2,4] triazin-3-yl]-{4-[2-(1-oxy -pyrrolidin-1-yl)-ethoxy]-phenyl}-amine). Drug. Drug Metab Dispos. 2007;35:929–36.
Iwanaga K, Ono S, Narioka K, Morimoto K, Kakemi M, Yamashita S et al. Oral delivery of insulin by using surface coating liposomes improvement of stability of insulin in GI tract. Int J Pharm. 1997;157:73–80.
Kamiya S, Yamada M, Kurita T, Miyagishima A, Arakawa M, Sonobe T. Preparation and stabilization of nifedipine lipid nanoparticles. Int J Pharm. 2008;354:242–7.
Katare OP, Vyas SP, Dixit VK. Preparation and performance evaluation of plain proliposomal systems for cytoprotection. J Microencaps. 1991;8:295–300.
Katsuragi Y, Mitsui Y, Umeda T, Otsuji K, Yamasawa S, Kurihara K. Basic Studies for the Practical Use of Bitterness Inhibitors: Selective Inhibition of Bitterness by Phospholipids. Pharm Res. 1997;14:720–4.
Khoo SM, Shackleford DM, Porter CJ, Edwards GA, Charman WN. Intestinal lymphatic transport of halofantrine occurs after oral administration of a unit-dose lipid-based formulation to fasted dogs. Pharm Res. 2003;20:1460–5.
Kisel MA, Kulik LN, Tsybovsky IS, Vlasov AP, Vorob'yov MS, Kholodova EA et al. Liposomes with phosphatidylethanol as a carrier for oral delivery of insulin: studies in the rat. Int J Pharm. 2001;216:105–14.
Kiviluoto T, Paimela H, Mustonen H, Kivilaakso E. Exogenous surface-active phospholipid protects necturus gastric mucosa against luminal acid and barrier-breaking agents. Gastroenterology. 1991;100:38–46.
Koo SI, Noh SK. Phosphatidylcholine inhibits and lysophosphatidylcholine enhances the lymphatic absorption of alpha-tocopherol in adult rats. J Nutr. 2001;131:717–22.
Koch A. Nebenwirkungen der Immunsuppression mit Sirolimus®, Cyclosporin A und Kortison im Vergleich mit der Standard-Triple-Drug-Therapie nach Nierentransplantation. Inaugural-Dissertation, Universitätsklinikum Münster, 2005.
Kovarik JM, Mueller EA, van Bree JB, Flückiger SS, Lange H, Schmidt B, Boesken WH, Lison AE, Kutz K. Cyclosporine pharmacokinetics and variability from a microemulsion formulation--a multicenter investigation in kidney transplant patients. Transplantation. 1994;58:658–63.
Kuentz M, Wyttenbach N, Kuhlmann O. Application of a statistical method to the absorption of a new model drug from micellar and lipid formulations - evaluation of qualitative excipient effects. Pharm Dev Technol. 2007;12:275–83.
Lamprecht A, Saumet JL, Roux J, Benoit JP. Lipid nanocarriers as drug delivery system for ibuprofen in pain treatment. Int J Pharm. 2004;278:407–14.
Lanza FL, Marathi UK, Anand BS BS, Lichtenberger LM. Clinical trial: comparison of ibuprofen-phosphatidylcholine and ibuprofen on the gastrointestinal safety and analgesic efficacy in osteoarthritic patients. Aliment Pharmacol Ther. 2008;28:431–42.
Leigh M, van Hoogevest P, Tiemessen H. Optimising the oral bioavailability of the poorly water-soluble drug cyclosporin A using membrane lipid technology. Drug Deliv Syst. 2001;1:73–7.
Leyck S, Dereu N, Etschenberg E, Ghyczy M, Graf E, Winkelmann J et al. Improvement of gastric tolerance of non-sterodial anti-inflammatory drugs by polyene phosphatidylcholine. Eur J Pharm. 1985;117:35–42.
Li H, An JH, Park JS, Han K. Multivesicular liposomes for oral delivery of recombinant human epidermal growth factor. Arch Pharm Res. 2005;28:988–94.
Lichtenberger LM, Wang ZM, Romero JJ, Ulloa C, Perez JC, Giraud MN et al. Non-steroidal anti-inflammatory drugs (NSAIDs) associate with zwitterinoic phospholipids: insight into the mechaniam and reversal of NSAID-induced gastrointestinal injury. Nat Med. 1995;1:154–8.
Lichtenberger LM, Romero JJ, Dial EJ. Surface phospholipids in gastric injury and protection when a selective cyclooxygenase-2 inhibitor (Coxib) is used in combination with aspirin. Br J Pharmacol. 2007;150:913–9.
Lichtenberger LM, Romero JJ, Kao YC, Dial EJ. Gastric protective activity of mixtures of saturated polar and neutral lipids in rats. Gastroenterology. 1990;99:311–26.
Lichtenberger LM, Romero JJ, Dial EJ, Moore JE. Naproxen-PC: A GI safe and highly effective anti- inflammatory. Inflammopharmacology. 2009;17:1–5.
Ling SS, Yuen KH, Magosso E, Barker SA. Oral bioavailability enhancement of a hydrophilic drug delivered via folic acid-coupled liposomes in rats. J Pharm Pharmacol. 2009;61:445–9.
Mann JF, Shakir E, Carter KC, Mullen AB, Alexander J, Ferro VA. Lipid vesicle size of an oral influenza vaccine delivery vehicle influences the Th1/Th2 bias in the immune response and protection against infection. Vaccine. 2009;27:3643–9.
Manosroi A, Bauer KH. Effects of gastrointestinal administration of human insulin and Insulin-DEAE Dextran complex entrapped in different compound liposomes on blood glucose in rats. Abstract; 1990.
Masuda K, Horie K, Suzuki R, Takayoshi Y, Hirano K. Oral delivery of antigens in liposomes with some lipid compositions modulates oral tolerance to the antigens. Microbiol Immunol. 2002;46:55–8.
Mehner W, Mader K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev. 2001;47:165–9.
Morishita M, Peppas NA. Is the oral route possible for peptide and protein drug delivery? Drug Discov Today. 2006;11:905–10.
Muller RH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery—a review of the state of the art. Eur J Pharm Biopharm. 2000;50:161–77.
Muller RH, Lippacher A, Gohla S. Solid lipid nanoparticles (SLN) as carrier system for the controlled release of drugs. Handbook of pharmaceutical controlled release technology. Marcel Dekker., 2000, pp 377–91.
Müller RH, Radtke M, Wissing SA. Nanostructured lipid matrices for improved microencapsulation of drugs. Int J Pharm. 2002;242:121–8.
Müller RH, Weyhers H, Muhlen AZ. Solid lipid nanoparticles (SLN)-ein neuartiger Wirkstoff-Carrier fur Kosmetika und Pharmazeutika: I. Systemeigenschaften, Herstellung and Scaling up. Pharm Ind. 1997;59:423–7.
Müller RH, Dingler A, Weyhers H. Solid lipid nanoparticles—ein neuartiger Wirkstoffcarrier fur Kosmetika und Pharmazeutika. 3. Mitteilung: Langzeitstabilität und Toxizitat, Anwendung in Kosmetika und Pharmazeutika. Pharm Ind. 1997;59:614–9.
Nakamura T, Tanigake A, Miyanaga Y, Ogawa T, Akiyoshi T, Matsuyama K, Uchida T. The effect of various substances on the suppression of the bitterness of quinine-human gustatory sensation, binding, and taste sensor studies. Chem Pharm Bull (Tokyo). 2002;50:1589–93.
Nicolaos G, Crauste-Manciet S, Farinotti R, Brossard D. Improvement of cefpodoxime proxetil oral absorption in rats by an oil-in-water submicron emulsion. Int J Pharm. 2003;263:165–71.
Nornoo AO, Zheng H, Lopes LB, Johnson-Restrepo B, Kannan K, Reed R. Oral microemulsions of paclitaxel: In situ and pharmacokinetic studies. Eur J Pharm Biopharm. 2009;71:310–7.
Odeberg JM, Kaufmann P, Kroon KG, Höglund P. Lipid drug delivery and rational formulation design for lipophilic drugs with low oral bioavailability, applied to cyclosporine. Eur J Pharm Sci. 2003;20:375–82.
Ogue S, Takahashi Y, Onishi H, Machida Y. Preparation of double liposomes and their efficiency as an oral vaccine carrier. Biol Pharm Bull. 2006;29:1223–8.
Pagonis TA, Koukoulis GN, Hadjichristodoulou CS, Toli PN, Angelopoulos NV. Multivitamins and phospholipids complex protects the hepatic cells from androgenic-anabolic-steroids-induced toxicity. Clin Toxicol. 2008;46:57–66.
Parnham MJ, Leyck S. PHOSPHOLIPON 100, New use. Drugs Fut. 1988;13:324–5.
Park H-J, Lee C-M, Lee Y-B, Lee K-Y. Controlled release of cyclosporin A from liposomes-in-microspheres as an oral delivery system. Biotech Bioproc Engin. 2006;11:526–9.
Porter JH, Trevaskis NL, Charman WN. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov. 2007;6:231–48.
Potluri P, Betageri GV. Mixed-micellar proliposomal systems for enhanced oral delivery of progesterone. Drug Del. 2006;13:227–32.
Poullain-Termeau S, Crauste-Manciet S, Brossard D, Muhamed S, Nicolaos G. Effect of oil-in-water submicron emulsion surface charge on oral absorption of a poorly water-soluble drug in rats. Drug Deliv. 2008;15:503–14.
Priano L, Esposti D, Esposti R, Castagna G, De Medici C, Fraschini F et al. Solid lipid nanoparticles incorporating melatonin as new model for sustained oral and transdermal delivery systems. J Nanosci Nanotechnol. 2007;7:3596–601.
Raffin RP, Colombo P, Sonvico F. Soft agglomerates of pantoprazole gastro-resistant microparticles for oral administration and intestinal release. J Drug Del Sci Tech. 2007;17:407–13.
Rao R, Squillante 3 rd E, Kim KH. Lipid-based cochleates: a promising formulation platform for oral and parenteral delivery of therapeutic agents. Crit Rev Ther Drug Carrier Syst. 2007;24:41–61.
Rao SV, Agarwal P, Shao J. Self-nanoemulsifying drug delivery systems (SNEDDS) for oral delivery of protein drugs: II. In vitro transport study. Int J Pharm. 2008;362:10–5.
Rao SV, Yajurvedi K, Shao L. Self-nanoemulsifying drug delivery system (SNEDDS) for oral delivery of protein drugs: III. In vivo oral absorption study. Int J Pharm. 2008;362:16–9.
Rao SV, Shao J. Self-nanoemulsifying drug delivery systems (SNEDDS) for oral delivery of protein drugs: I. Formulation development. Int J Pharm. 2008;362:2–9.
Renou C, Carrière F, Ville E, Grandval P, Joubert-Collin M, Laugier R. Effects of lansoprazole on human gastric lipase secretion and intragastric lipolysis in healthy human volunteers. Digestion. 2001;63:207–13.
Robinson JR. Introduction: Semi-solid formulations for oral drug delivery. Bulletin Technique Gattefossé, 1996;11–13.
Yoo HS, Park TG. Biodegradable nanoparticles containing protein-fatty acid complexes for oral delivery of salmon calcitonin. Pharm Sci. 2004;93:488–95.
Schote U, Ganz P, Fahr A, Seelig J. Interactions of cyclosporines with lipid membranes as studied by solid-state nuclear magnetic resonance spectroscopy and high-sensitivity titration calorimetry. Pharm Sci. 2002;91:856–67.
Semalty A, Semalty M, Singh D, Rawat MSM. Development and physicochemical evaluation of pharmacosomes of diclofenac. Acta Pharm. 2009;59:335–44.
Shah NM, Parikh J, Namdeo A, Subramanian N, Bhowmick S. Preparation, characterization and in vivo studies of proliposomes containing Cyclosporine A. J Nanosci Nanotechnol. 2006;6:2967–73.
Soehngen EC. Encapsulation of indomethacin in liposomes provides protection against both gastric and intestinal ulceration when orally administered to rats. Arthr Rheumat. 1987;31:1–10.
Suresh G, Manjunath K, Venkateswarlu V, Satyanarayana V. Preparation, characterization, and in vitro and in vivo evaluation of lovastatin solid lipid nanoparticles. AAPS PharmSciTech 8: Article 24 (2007).
Tabak A, et al. Evaluation of oral TG100435 formulations based on exposure studies in rat and dog. Targegen Inc.; The AAPS Journal Abstract (www.aapsj.org/abstracts/AM_2006/staged/AAPS2006-000603.pdf) 2006.
Takagi S, Toko K, Wada K, Ohki T. Quantification of Suppression of Bitterness Using an Electronic Tongue. J Pharm Sci. 2001;90:2042–8.
Takahashi M, Uechi S, Takara K, Asikin Y, Wada KE. Evaluation of an oral carrier system in rats: bioavailability and antioxidant properties of liposome-encapsulated Curcumin. J Agric Food Chem. 2009;57:9141–6.
Thirawong N, Thongborisute J, Takeuchi H, Sriamornsak P. Improved intestinal absorption of calcitonin by mucoadhesive delivery of novel pectin-liposome nanocomplexes. J Contr Rel. 2008;125:236–45.
Thongborisute J, Tsuruta A, Kawabata Y, Takeuchi H. The effect of particle structure of chitosan-coated liposomes and type of chitosan on oral delivery of calcitonin. J Drug Target. 2006;14:147–54.
Tiwari SB, Amiji MM. Improved oral delivery of paclitaxel following administration in nanoemulsion formulations. J Nanosci Nanotechnol. 2006;6:3215–21.
Tiwari SB, Shenoy DB, Amiji MM. Nanoemulsion formulations for improved oral delivery of poorly soluble drugs. NSTI-Nanotech 2006, Vol.1.
Trevaskis NL, Charman WN, Porter CJ. Lipid-based delivery systems and intestinal lymphatic drug transport: a mechanistic update. Adv Drug Deliv Rev. 2008;60:702–16.
Trevaskis NL, Porter CJH, Charman WN. The lymph lipid precursor pool is a key determinant of intestinal lymphatic drug transport. J Pharmacol Exp Ther. 2006;316:881–91.
Uner M. Preparation, characterization and physico-chemical properties of solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC): their benefits as colloidal drug carrier systems. Pharmazie. 2006;61:375–86.
van den Bosch H, Postema NM, de Haas GH, van Deenen LL. On the positional specificity of phospholipase A from pancreas. Biochim Biophys Acta. 1965;98:657–9.
Varshosaz J, Minayian M, Moazen E. Enhancement of oral bioavailability of pentoxifylline by solid lipid nanoparticles. J Liposome Res. 2009 Aug 20. [Epub ahead of print].
Wang S, Sun M, Ping Q. Enhancing effect of Labrafac Lipophile WL 1349 on oral bioavailability of hydroxysafflor yellow A in rats. Int J Pharm. 2008;358:198–204.
Werle M, Takeuchi H. Chitosan-aprotinin coated liposomes for oral peptide delivery: development, characterisation and in vivo evaluation. Int J Pharm. 2009;370:26–32.
Wissing SA, Kayser O, Muller RH. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev. 2004;56:1257–72.
Xu H, He L, Nie S, Guan J, Zhang X, Yang X et al. Optimized preparation of vinpocetine proliposomes by a novel method and in vivo evaluation of its pharmacokinetics in New Zealand rabbits. J Control Rel. 2009;140:61–8.
Yang L, Geng Y, Li H, Zhang Y, You J, Chang Y. Enhancement the oral bioavailability of praziquantel by incorporation into solid lipid nanoparticles. Pharmazie. 2009;64:86–9.
Yang S, Zhu J, Lu Y, Liang B, Yang C. Body Distribution of camptothecin solid lipid nanoparticles after oral administration. Pharm Res. 1999;16:751–7.
Yanagawa A, Iwayama T, Saotome T, Shoji Y, Takano K, Oka H et al. Selective transfer of cyclosporin to thoracic lymphatic system by the application lipid microspheres. J Microencapsul. 1989;6:161–4.
Zhang N, Ping Q, Huang G, Xu W, Cheng Y, Han X. Lectin-modified solid lipid nanoparticles as carriers for oral administration of insulin. Int J Pharm. 2006;327:153–9.
Zhang N, Ping Q, Huang G, Han X, Cheng Y, Xu W. Transport characteristics of wheat germ agglutinin-modified insulin-liposomes and solid lipid nanoparticles in a perfused rat intestinal model. J Nanosci Nanotechnol. 2006;6:2959–66.
Zhang Z, Lv H, Zhou J. Novel solid lipid nanoparticles as carriers for oral administration of insulin. Pharmazie. 2009;64:574–8.
Zou W, Sun W, Zhang N, Xu W. Enhanced oral bioavailability and absorption mechanism study of N3-O-toluyl-fluorouracil-loaded liposomes. J Biomed Nanotechnol. 2008;4:90–8.
van den Bosch H, Postema NM, de Haas GH, van Deenen LL. On the positional specificity of phospholipase A from pancreas. Biochim Biophys Acta. 1965;98:657–9.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fricker, G., Kromp, T., Wendel, A. et al. Phospholipids and Lipid-Based Formulations in Oral Drug Delivery. Pharm Res 27, 1469–1486 (2010). https://doi.org/10.1007/s11095-010-0130-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11095-010-0130-x